Lineage Cell Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $113.0M | $9.5M |
| FY2020 | — | $96.2M | $32.6M |
| FY2021 | — | $92.2M | $55.7M |
| FY2022 | — | $73.3M | $11.4M |
| FY2023 | — | $63.4M | $35.4M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2019 | — | $113.0M | $9.5M |
| FY2020 | — | $96.2M | $32.6M |
| FY2021 | — | $92.2M | $55.7M |
| FY2022 | — | $73.3M | $11.4M |
| FY2023 | — | $63.4M | $35.4M |